Acceleration Advantage NeoClone's exclusive ABL-MYC retroviral transformation system enables faster and more cost-effective production of monoclonal antibodies, creating a strong value proposition for customers needing rapid custom antibodies.

Partnership Growth With a small team and limited revenue, NeoClone can scale through strategic partnerships with larger CROs, distributors, or contract manufacturers to expand reach, capacity, and co-development opportunities for NeoAb antibodies.

SMB Focus Target small to mid-size biotech firms and academic labs that require customizable antibodies, emphasizing speed and cost savings to win pilots, early projects, and recurring orders.

Midwest Advantage Leverage Madison location near universities and biotech clusters to pursue regional collaboration, grant programs, and university-led pilot projects that can validate and accelerate customer adoption.

Digital Sales Enhance marketing and sales enablement through a modern CRM and e-commerce capability, and consider expanding services such as antibody validation and screening to complement the NeoClone portfolio.